

The UAB Institutional Biosafety Committee Meeting Minutes
Research Involving Recombinant and Synthetic Nucleic Acid Molecules
July 09, 2026, 9:00 am

Members	Present (Y/N)	Vote (Y/N)
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Megan Kiedrowski, PhD, Vice-Chair [MRK]	Y	Y
3. Donna Williamson, MS, RSS [DSW]	Y	Y
4. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	Y	N
5. Cameron Crosby, MD, OM [JCC]	N	N
6. Julie Allen, DNP, OM [JSA]	Y	Y
7. Lillie Flood, RN-BSN, JCDH [LF]	Y	Y
8. Qiang (John) Ding, PhD, VA [QJD]	Y	Y
9. Andrea Osborne, DVM, ARP [AJO]	N	N
10. Justin Roth, PhD, EHS [JCR]	N	N
11. Brian Lagory, BS, BSO-EHS [BEL]	Y	Y
12. Vineel Reddy, PhD, BSO-EHS [VPR]	Y	Y
13. Julie Gray, BS, EHS [JDG]	Y	N
14. Tyler Uzzell, MA, IRB [TWU]	Y	Y
15. Amanda J. Watts, MS, IACUC [AJW]	Y	Y
16. Chad Dunaway, IACUC [CD]	Y	N
17. Masakazu Kamata, PhD, Lab Rep [MK]	Y	Y
18. Kevin Harrod, PhD, Lab Rep [KH]	N	N
19. Christine M. Wright, PhD, Lab Rep [CMW]	Y	Y
20. Larisa Pereboeva, PhD, Lab Rep [LP]	Y	Y
21. Theresa Strong, PhD, Lab Rep [TVS]	N	N
22. Aftab Ahmad, PhD, Lab Rep [AA]	Y	Y
23. Adam McClintock, MBA, HSR [AM]	N	N
24. Wesley Willeford, MD, JCDH [WW]	Y	Y
25. Rebecca Johnstone, Recording Secretary [RMJ]	Y	N
Total	19	15

Guests Present

Laura Caltrider, MS, EHS [LPC]	Riley Cooper, MS, EHS [RC]
I'Aisha Hampton, EHS [IH]	Douglas Fox, PhD, SEBLAB [DMF]
Joseph Palmer, PhD, SEBLAB [JP]	Earle Durboraw, MS, ARP [ED]
Susan Pelmer, RSS [SP]	Ian Doty, EHS [ED]
Phillip Richter, DVM, PhD, ARP [PJR]	Caitlyn Sebastian, GBS [CS]

The July 09, 2026, Institutional Biosafety Committee (IBC) meeting for research involving recombinant of synthetic nucleic acid molecules was called to order at 9:02 a.m. via web-based video conferencing tool by the Chair. A quorum was present.

Welcome and Introduction of Guests

The Chair welcomed all in attendance.

Approval of June 11, 2026, Minutes

The June 11, 2026, meeting minutes were distributed in the Committee member's packets via email and/or secure cloud storage prior to the meeting. A motion was made to approve the minutes. The motion was seconded. There were three (3) abstentions. The minutes were approved.

Standing Reports

- In the News/Regulatory Visits – There was no update.
- Faculty Senate – The new Handbooks were approved by Faculty Senate.
- Veterans Administration – There was no update.
- Employee Health – There was no update.
- ARP/Facilities Operations Report – The report on facility upgrades included RSB bulk autoclaves, cage wash operations, and ongoing repairs across different buildings.
- JCDH – There was no update.
- EHSA – It was reported that development of the bioform and certain reporting functions were ongoing.
- Research Safety Updates
 - PI Arrivals/Departures/UAB Lab Relocations – Departing – Austin retiring.
 - Safety Visits – The top five safety issues reported for the past month were: chemical inventory reconciliation, chemical secondary containment, biosafety cabinet certifications, chemical SOPs and peroxide handling.
- Ongoing Business
 - NIH Noncompliance Reports – There were no updates.
- New Business
 - NIH requests re: Executive Order 142902 - It was reported that several researchers had received requests to justify that their research did not fall under dangerous gain of function activities. The updated DURC-PEPP requirements were listed on the IBC website.
- Project Review - The review and discussion of projects included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.
- Announcements/Discussions – Next meeting date: Thursday, August 13, 2026, 9:00 am

Adjournment

The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 9:49 am.

Respectfully submitted by:

A handwritten signature in black ink, appearing to read 'Rebecca Johnstone', written over a horizontal line.

July 09, 2026

Rebecca Johnstone, Recording Secretary
Research Safety Committees

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Not Approve	Abstain or Recuse	RSC #	Evaluation
0	15	0	26-101	(III.C.1) Arora, Pankaj; A Phase 1/2, First-in-Human, Open-Label, Multicenter, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NVC-001, a Novel Adeno-Associated Virus (Serotype 9) Vector Expressing a Dominant Negative SUN1 Transgene, in Patients with LMNA-Related Dilated Cardiomyopathy Reasons for IBC: Administration of rsNA single-stranded AAV9 vector that encodes a dominant-negative form of naturally occurring human dnSUN1 to one or more human subjects. The IBC deferred this project to the August 2026 IBC meeting to collect more information about viral vector shedding from the PI, the sponsor, and to seek guidance from the NIH.
15	0	0	26-096	(III.D.1.b; III.D.4) Dutt, Taro; Trafficking of Mycobacterium tuberculosis Virulence Proteins and Their Role in Disease Progression in Mice Reasons for IBC: - Experiments with wild-type and mutant strains of Mycobacterium tuberculosis, a Risk Group 3 (RG3) organism, including administration to animals. Containment Requirements: - SEBLAB/BSL3 practices and procedures must be used for all in vitro work with RG3 agents. - SEBLAB/BSL3 practices and procedures must be used for all animal work involving RG3 agents.
15	0	0	26-083	(III.D.1.a; III.D.4.a) Osuka, Satoru; Collagen-binding Cytokines and Antibodies for Malignant Brain Tumors Reasons for IBC: - Administration of r/sNA lentivirus (LV) modified animal cells to animals - Administration of Adeno-associated viral (AAV) vectors to animals Containment Requirements: - BSL1 practices and procedures may be used for in vitro manipulations of AAV. - BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, must be used for all work with LV.

				• ABSL2 practices and procedures, including the posting of and AUSI, must be used for 14 days after the last AAV administration, then BSL1 should suffice. • ABSL1 practices and procedures may be used for administration of modified animal cell lines. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with lentiviral vectors.
15	0	0	26-090	(III.D.1; III.D.4) Xu, Jia; Genetics and Epigenetics in Cancer Development Reasons for IBC: • Creation of r/sNA human and animal cell lines using Lentiviral/CRISPR • Administration of r/sNA human and animal cell lines to animals Containment Requirements: • BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, must be used for all work with LV. • ABSL1 practices and procedures may be used for administration of modified animal cell lines. • The UAB Guidelines for Conducting Human Xenograft Experiments in Mice or ABSL1 practices and procedures must be followed for the administration of human material to animals, as applicable. • The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with lentiviral vectors.
15	0	0	26-099	(III.D.4) Gamble, Karen; Food Intake Timing on Circadian Control of Blood Pressure in Diet-Induced Obesity Reason for IBC: • Administration of Adeno-associated viral (AAV) vectors to animals Containment Requirements: • BSL1 practices and procedures may be used for in vitro manipulation of AAV. • ABSL2 practices and procedures, including the posting of an AUSI, must be used for 14 days after the last AAV administration, then ABSL1 should suffice.
15	0	0	26-089	(III.D.4.a) Kim, Yu-Shin; Trigeminal Ganglia Imaging and Immune Cell Infiltration Reason for IBC: • Administration of Adeno-associated viral (AAV) vectors to animals Containment Requirements: • BSL1 practices and procedures may be used for in vitro manipulation of AAV.

				ABSL2 practices and procedures, including the posting of an AUSI, must be used for 14 days after the last AAV administration, then ABSL1 should suffice.
15			26-084	(III.D.4) Nabors, Burt; Programmable Immuno Electrotherapy For GBM Reason for IBC: - Administration of modified murine cell lines expressing reported genes to animals Containment Requirements: - BSL1 practices and procedures may be used for manipulation of murine cell lines. - ABSL1 practices and procedures may be used for administration of modified murine cell lines.
15	0	0	26-080	(III.D.4) Niwa, Minae; Maternal Early Life Adversity Disrupts Offspring Social Brain Development and Behavior Reason for IBC: - Administration of Adeno-associated viral (AAV) vectors to animals Containment Requirements: - BSL1 practices and procedures may be used for in vitro manipulation of AAV. - ABSL2 practices and procedures, including the posting of an AUSI, must be used for 14 days after the last AAV administration, then ABSL1 should suffice.
15	0	0	26-081	(III.D.4) Raju, Vamsee; Inhaled Nitric-Oxide Releasing Prodrug to Treat Bacterial Infections Reason for IBC: - Experiments with wild-type and recombinant Risk Group 2 (RG2) microorganisms, Klebsiella Pneumoniae and Pseudomonas aeruginosa, including administration to animals Containment Requirements: - BSL2 practices and procedures, including the use of an annually certified BSC, must be used for all in vitro work with RG2 bacteria. - ABSL2 practices and procedures, including the use of an annually certified BSC, must be used for all animals that have been administered RG2 bacteria. - The Animal Resources Program will be notified, via the posting of an AUSI, of RG2 agents in animals. - Agent Specific Safety and Data Plans must be made available and reviewed by all personnel working with RG2 agents.

				A copy of the AUSI must accompany animals in transport to imaging and IACUC SOP: "Transportation of Animals Procedure" must be followed.
15	0	0	25-172	(III.D.4.b) Sun, Xingshen; Genetic Cell Lineage Tracing in Ferrets Reason for IBC: - Experiments with transgenic animals not in Order Rodentia Containment Requirements: - Standard ferret handling procedures may be used.
15	0	0	26-095	(III.E) Dokland, Terje; Structural Basis for HIV-1 Gag Interactions with Cellular and Viral Constituents Reason for IBC: - Experiments with non-K-12 E. coli strains (BL21) Containment Requirements: - All BL21 waste must be disposed as biohazard waste.